Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 711? excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711? is a trademark of Sirigen Group Ltd.

Clone 93 can be used for blocking of CD16/CD32 interactions with the Fc domain of immunoglobulins, but is not the same clone as 2.4G2.

The 93 mAb is specific to the common epitope of CD16/CD32. Additional reported applications (for the relevant formats) include: immunoprecipitation¹ and blocking of Fc-mediated reactions in functional studies^2,4,23. It is useful for blocking non-specific binding of immunoglobulin to Fc receptors. For blocking of Fc receptors in flow cytometric analysis, pre-incubate the cells with purified anti-CD16/CD32 antibody (=1.0 ?g per 10⁶ cells in 100 ?L volume) for 5-10 minutes on ice prior to immunostaining. For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 101330) (Endotoxin <0.01 EU/?g, Azide-Free, 0.2 ?m filtered).

1. Personal communication (IP)
2. Oliver AM, et al. 1999. Hybridoma 18:113. (Block)
3. Brummel R and Lenert P. 2005. J. Immunol. 174:2429.
4. Terrazas LI, et al. 2005. Int. J. Parasitol. 35:1349. (Block)
5. Clements JL, et al. 2006. J. Immunol. 177:905.
6. Mohamed W, et al. 2010. Infect Immun. 78:3306. PubMed
7. Ouchi T, et al. 2011. J. Exp Med. 208:2607. PubMed
8. Kmieciak M, et al. 2011. J. Vis. Exp. 47:2381. PubMed
9. Yamazaki S, et al. 2012. PLoS One. 7:e51665. PubMed
10. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
11. Azuma M, et al. 2012. Oncoimmunology. 1:581. PubMed
12. Koon HW, et al. 2013. J. Vis. Exp. 68:4208. PubMed
13. Hegde VL, et al. 2013. J Biol Chem. 288:36810. PubMed
14. Huang J, et al. 2013. J. Immunol Methods. 387:254. PubMed
15. Dutow P, et al. 2014. J Infect Dis. PubMed
16. Fan Y, et al. 2014. J Exp Med. 211:313. PubMed
17. Huang HN, et al. 2014. Antimicrob Agents Chemother. 58:1538. PubMed
18. Takei S, et al. 2014. Vaccine. 32:3066. PubMed
19. Richardson ML, et al. 2014. PLoS Negl Trop Dis. 8:2825. PubMed
20. Cekanaviciute E, et al. 2014. J Immunol. 193:139. PubMed
21. Kimura T, et al. 2014. Int Immunol. 26:697. PubMed
22. Everad A, et al. 2014. Nat Commun. 5:5648. PubMed
23. Cenci E, et al. 2006. J. Leuko. Biol. 79(1):40-5. (Block)

1. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
2. LeBlond ND, et al. 2020. J Lipid Res. 61:1697. PubMed
3. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
4. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
5. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
6. LeBlond ND, et al. 2020. J Lipid Res. 61:1697. PubMed
7. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
8. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
9. Chavez JS, et al. 2022. Cells. 11:. PubMed
10. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
11. Liu Q, et al. 2016. Cell Death Dis. 1.93125. PubMed
12. Pessoa Rodrigues C, et al. 2020. Sci Adv. 6:eaaz4815. PubMed

B cells, monocyte/macrophages, NK cells, neutrophils, mast cells, dendritic cells

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Unkeless JC. 1989. J. Clin. Invest. 83:355.
3. Qiu WQ, et al. 1990. Science 248:732.